VRTX

SEC source: 0001209191-22-006767 · doc4.xml · nonDerivative · entry 1

Arbuckle Stuart A · CIK 0001557290 · EVP, COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,903

F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/06/2019 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2022 and the shares will vest on 02/24/2022.

SEC source: 0001209191-22-006770 · doc4.xml · nonDerivative · entry 3

Bozic Carmen · CIK 0001790029 · EVP and CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,941

F3 · shares: Restricted stock unit award that vests in installments beginning on 02/24/2023.

SEC source: 0001209191-22-006770 · doc4.xml · nonDerivative · entry 2

Bozic Carmen · CIK 0001790029 · EVP and CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,679

F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2021 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2022 and the shares will vest in installments beginning on 02/17/2022.

SEC source: 0001209191-22-006770 · doc4.xml · nonDerivative · entry 1

Bozic Carmen · CIK 0001790029 · EVP and CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,051

F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 05/20/2019 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2022 and the shares will vest on 02/24/2022.

SEC source: 0001209191-22-006775 · doc4.xml · nonDerivative · entry 3

Kewalramani Reshma · CIK 0001735944 · Director · CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 141,703

F3 · shares: Restricted stock unit award that vests in installments beginning on 02/24/2023.

SEC source: 0001209191-22-006775 · doc4.xml · nonDerivative · entry 2

Kewalramani Reshma · CIK 0001735944 · Director · CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 112,586

F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2021 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2022 and the shares will vest in installments beginning on 02/17/2022.

SEC source: 0001209191-22-006775 · doc4.xml · nonDerivative · entry 1

Kewalramani Reshma · CIK 0001735944 · Director · CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 83,554

F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/06/2019 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2022 and the shares will vest on 02/24/2022.

SEC source: 0001209191-22-006779 · doc4.xml · nonDerivative · entry 3

LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 116,605

F3 · shares: Restricted stock unit award that fully vested upon grant.

SEC source: 0001209191-22-006779 · doc4.xml · nonDerivative · entry 2

LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 99,160

F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2021 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2022 and the shares will vest on 02/17/2022.

SEC source: 0001209191-22-006779 · doc4.xml · nonDerivative · entry 1

LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 78,232

F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/06/2019 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2022 and the shares will vest on 02/24/2022.

SEC source: 0001209191-22-006786 · doc4.xml · nonDerivative · entry 3

Liu Joy · CIK 0001847529 · SVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,194

F3 · shares: Restricted stock unit award that vests in installments beginning on 02/24/2023.

SEC source: 0001209191-22-006786 · doc4.xml · nonDerivative · entry 2

Liu Joy · CIK 0001847529 · SVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,987

F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2021 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2022 and the shares will vest in installments beginning on 02/17/2022.

SEC source: 0001209191-22-006786 · doc4.xml · nonDerivative · entry 1

Liu Joy · CIK 0001847529 · SVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,353

F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/06/2019 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2022 and the shares will vest on 02/24/2022.

SEC source: 0001209191-22-006788 · doc4.xml · nonDerivative · entry 3

Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 61,566

F3 · shares: Restricted stock unit award that vests in installments beginning on 02/24/2023.

SEC source: 0001209191-22-006788 · doc4.xml · nonDerivative · entry 2

Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,356

F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2021 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2022 and the shares will vest in installments beginning on 02/17/2022.

SEC source: 0001209191-22-006788 · doc4.xml · nonDerivative · entry 1

Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,728

F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/06/2019 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2022 and the shares will vest on 02/24/2022.

SEC source: 0001209191-22-006794 · doc4.xml · nonDerivative · entry 3

Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,257

F3 · shares: Restricted stock unit award that vests in installments beginning on 02/24/2023.

SEC source: 0001209191-22-006794 · doc4.xml · nonDerivative · entry 2

Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,995

F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2021 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2022 and the shares will vest in installments beginning on 02/17/2022.

SEC source: 0001209191-22-006794 · doc4.xml · nonDerivative · entry 1

Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,043

F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/06/2019 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2022 and the shares will vest on 02/24/2022.

SEC source: 0001209191-22-006792 · doc4.xml · nonDerivative · entry 3

Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,992

SEC source: 0001209191-22-006792 · doc4.xml · nonDerivative · entry 2

Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,518

F2 · shares: Restricted stock unit award that vests in installments beginning on 02/24/2023.

SEC source: 0001209191-22-006792 · doc4.xml · nonDerivative · entry 1

Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,204

F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2021 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2022 and the shares will vest in installments beginning on 02/17/2022.

SEC source: 0001209191-22-006796 · doc4.xml · nonDerivative · entry 3

WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,379

F3 · shares: Restricted stock unit award that vests in installments beginning on 02/24/2023.

SEC source: 0001209191-22-006796 · doc4.xml · nonDerivative · entry 2

WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,117

F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2021 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2022 and the shares will vest in installments beginning on 02/17/2022.

SEC source: 0001209191-22-006796 · doc4.xml · nonDerivative · entry 1

WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,489

F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 04/10/2019 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2022 and the shares will vest on 02/24/2022.

SEC source: 0001209191-22-005895 · doc4.xml · derivative · entry 6

MCGLYNN MARGARET G · CIK 0001215126 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 5,000 shares

Expires 2025-05-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: Fully vested.

SEC source: 0001209191-22-005895 · doc4.xml · nonDerivative · entry 5

MCGLYNN MARGARET G · CIK 0001215126 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,099

F1 · kind: Transaction made pursuant to Ms. McGlynn's company approved trading plan under Rule 10b5-1.

F3 · price: Ms. McGlynn undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F6 · price: Open market sales reported on this line occurred at a weighted average price of $243.24 (range $243.21 to $243.27).

SEC source: 0001209191-22-005895 · doc4.xml · nonDerivative · entry 4

MCGLYNN MARGARET G · CIK 0001215126 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,311

F1 · kind: Transaction made pursuant to Ms. McGlynn's company approved trading plan under Rule 10b5-1.

F3 · price: Ms. McGlynn undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F5 · price: Open market sales reported on this line occurred at a weighted average price of $242.78 (range $242.18 to $243.14).

SEC source: 0001209191-22-005895 · doc4.xml · nonDerivative · entry 3

MCGLYNN MARGARET G · CIK 0001215126 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,398

F1 · kind: Transaction made pursuant to Ms. McGlynn's company approved trading plan under Rule 10b5-1.

F3 · price: Ms. McGlynn undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F4 · price: Open market sales reported on this line occurred at a weighted average price of $241.83 (range $241.16 to $242.15).

SEC source: 0001209191-22-005895 · doc4.xml · nonDerivative · entry 2

MCGLYNN MARGARET G · CIK 0001215126 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,198

F1 · kind: Transaction made pursuant to Ms. McGlynn's company approved trading plan under Rule 10b5-1.

F2 · price: Open market sales reported on this line occurred at a weighted average price of $240.53 (range $240.01 to $240.92).

F3 · price: Ms. McGlynn undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-22-005895 · doc4.xml · nonDerivative · entry 1

MCGLYNN MARGARET G · CIK 0001215126 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,099

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-22-003717 · doc4.xml · derivative · entry 1

MCKENZIE DIANA · CIK 0001754648 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 793.664

Underlying: Common Stock · 119.265 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death.

F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death.

F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death.

SEC source: 0001209191-22-003721 · doc4.xml · derivative · entry 1

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,672.338

Underlying: Common Stock · 189.739 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

SEC source: 0001209191-21-064731 · doc4.xml · nonDerivative · entry 2

ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,589

F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1.

F3 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F4 · price: Open market sales reported on this line occurred at a weighted average price of $187.51 (range $187.26 to $187.79).

SEC source: 0001209191-21-064731 · doc4.xml · nonDerivative · entry 1

ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,609

F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1.

F2 · price: Open market sales reported on this line occurred at a weighted average price of $186.80 (range $186.22 to $187.19).

F3 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-21-064738 · doc4.xml · nonDerivative · entry 2

Arbuckle Stuart A · CIK 0001557290 · EVP, COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,103

F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.

SEC source: 0001209191-21-064738 · doc4.xml · nonDerivative · entry 1

Arbuckle Stuart A · CIK 0001557290 · EVP, COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,104

F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.

F2 · price: Open market sales reported on this line occurred at a weighted average price of $186.99 (range $186.67 to $187.31).

F3 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-21-064740 · doc4.xml · nonDerivative · entry 2

Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,928

F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1.

F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F4 · price: Open market sales reported on this line occurred at a weighted average price of $187.48 (range $187.24 to $187.85).

SEC source: 0001209191-21-064740 · doc4.xml · nonDerivative · entry 1

Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,958

F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1.

F2 · price: Open market sales reported on this line occurred at a weighted average price of $186.78 (range $186.22 to $187.19).

F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-21-062676 · doc4.xml · nonDerivative · entry 1

Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,576

SEC source: 0001209191-21-060704 · doc4.xml · derivative · entry 1

MCKENZIE DIANA · CIK 0001754648 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 674.399

Underlying: Common Stock · 151.041 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death.

F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death.

F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death.

SEC source: 0001209191-21-060705 · doc4.xml · derivative · entry 1

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,482.599

Underlying: Common Stock · 240.293 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

SEC source: 0001209191-21-052881 · doc4.xml · nonDerivative · entry 2

Kewalramani Reshma · CIK 0001735944 · Director · CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,754

F2 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares purchased at each separate price.

F3 · price: Open market purchases reported on this line occurred at a weighted average price of $196.34 (range $195.74 to $196.58).

SEC source: 0001209191-21-052881 · doc4.xml · nonDerivative · entry 1

Kewalramani Reshma · CIK 0001735944 · Director · CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,511

F1 · price: Open market purchases reported on this line occurred at a weighted average price of $195.14 (range $194.63 to $195.50).

F2 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares purchased at each separate price.

SEC source: 0001209191-21-049602 · doc4.xml · nonDerivative · entry 1

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,210

F1 · price: Open market sales reported on this line occurred at a weighted average price of $197.91 (range $197.45 to $198.12).

F2 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares purchased at each separate price.

SEC source: 0001209191-21-049288 · doc4.xml · nonDerivative · entry 1

Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,342

SEC source: 0001209191-21-046901 · doc4.xml · derivative · entry 1

MCKENZIE DIANA · CIK 0001754648 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 523.358

Underlying: Common Stock · 138.889 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death.

F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death.

F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death.

SEC source: 0001209191-21-046903 · doc4.xml · derivative · entry 1

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,242.306

Underlying: Common Stock · 220.96 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

SEC source: 0001209191-21-038182 · doc4.xml · nonDerivative · entry 3

Bhatia Sangeeta N. · CIK 0001643921 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,191

F1 · kind: Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1.

F3 · price: Dr. Bhatia undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F5 · price: Open market sales reported on this line occurred at a weighted average price of $211.00 (range $210.70 to $211.50).

SEC source: 0001209191-21-038182 · doc4.xml · nonDerivative · entry 2

Bhatia Sangeeta N. · CIK 0001643921 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,312

F1 · kind: Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1.

F3 · price: Dr. Bhatia undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F4 · price: Open market sales reported on this line occurred at a weighted average price of $210.01 (range $209.64 to $210.34).